ELSEVIER

Contraception
1998;58:393–394

Author Index
Volume 58
July–December 1998

Aden, Ulrike, 75
Affandi, B., 99S
Al-Tamimi, Salah O., 193
Alagana, Federica, 69
Alexandersson, Maria, 157
Alonso, A., 7
Alvarez, Francisco, 211, 275
Amatya, Ramesh, 201
Angiolucci, Marco, 289
Arangino, Serenella, 289
Arjas, Elja, 361
Assmann, A., 321
Atterfelt, Paula, 157

Baird, David T., 99
Balasubramanian, S.P.A., 119
Bansode, F.W., 61, 175
Barrios, R., 7
Berényi, Mihály, 305
Bhardwaj, J.C., 165
Bianchedi, Diana, 69
Bianchi, Massimiliano, 69
Blye, Richard P., 129
Bobbink, I.W.G., 39
Bokström, Hans, 157
Brännström, Mats, 157
Brache, Vivian, 211, 275
Brown, Audrey H., 99
Burkman, Ronald T., 35S
Burleigh, David W., 45
Byrne, James D., 1

Cagnacci, Angelo, 289
Calvez, Thierry, 29
Carlucci, Clelia, 69
Carr, Bruce R., 23S
Carre, Nicholas, 29
Castañeda, Anibal, 21
Castle, Philip E., 51
Castro, Sara, 105
Cedeno, E., 7
Centola, Grace M., 35
Chakraborty, Smritinath, 183
Chauhan, S.C., 61
Chen, Chih-Ping, 295
Chompootaweep, S., 221
Chowdhury, S.R., 175
Cochon, Leila, 211
Coelingh Bennink, Herjan J.T., 39, 93, 215, 75S
Cone, Richard A., 51
Correa, Juan E., 21
Costa Paiva, Lúcia, 351
Crosignani, Pier Giorgio, 69
Croxatto, H.B., 91S

Daka, J., 153
Darney, Philip, 275
Das, H.C., 165
Das, S.K., 165
de Carvalho, João Ernesto, 309
de Lourdes Cristofoletti, Maria, 105
de Maat, M.P.M., 321
de Pádua, Karla S., 233, 239, 245, 251
Dick, A., 321
Dolder, Heidi, 309
Dominik, Rosalie, 379
Dorflinger, Laneta, 379
Douglas, A., 153
Dusitsin, N., 221
Dwivedi, A.K., 175

Earle, Brenda B., 375
Edström, Birgitte, 199
Egberg, Nils, 93
Ekani-Bessala, Marie-Madeleine, 29

Farr, Gaston, 201
Faúndes, Anibal, 105, 211, 351
Faúndes, Daniel, 105
Ferman, J.J., 7
Figueroa, J.G., 7
Franceschi, Silvia, 335
Fuziwara, J.L., 7

Garza-Flores, J., 7
Gharaibehand Maha, Munir N., 193
Ghosh, Deborah, 111
Gilmore, Caroline, 201
Gordon, Keith, 45
Grimes, David, 357
Gross, W., 83
Guevara, S.J., 7
Guha, Sujoy K., 165, 227
Gunnervik, Christina, 93

Hardy, Ellen, 105, 233, 239, 245, 251
Harrison, Polly F., 323
Heinemann, L.A.J., 321
Hertz-Picciotto, Irva, 375
Hild-Petito, Sheri, 129
Hinberg, I., 153
Hirvonen, Erkki, 93
Ho, P.C., 207
Hodgen, Gary D., 45
Hoen, Timothy E., 51
Hsiu, James G., 45
Hsu, Tzu-Chi, 295
Huber, Johannes, 283, 85S
Hulkko, Seppo, 93

Jain, John K., 1
Jiménez, Ana Luisa, 233, 239, 245, 251
Jung-Hoffmann, Claudia, 75, 83

Karia, S.R., 361
Karov, J., 153
Kaunitz, Andrew M., 15S
Khaosaad, Prayoonsak, 149
Klaisle, Cynthia, 275
Kluft, C., 321
Kochagarn, E., 221
Koul, Veena, 165, 227
Kreiner, Svend, 199
Kuhl, Herbert, 75, 83

La Vecchia, Carlo, 335
Lacarra, Maria D.C., 1, 275
Lala, Sanchaita, 183
Larsson-Cohn, Ulf, 93
Lewis, Curtis, 389
Lidegaard, Øjvind, 199
Lohiya, N.K., 119
Lolkema, A., 13
Longu, Giorgio, 289

Maikhuri, J.P., 175
Mäkäräinen, L., 91S
Makker, A., 61
Malhotra, R.L., 165
Manivannan, B., 119
Martin, Cameron W., 99
Martínez, Gustavo H., 21
Mascarenhas, Lawrence, 215, 79S
Mathur, Vineet, 165

© 1998 Elsevier Science Inc. All rights reserved.
655 Avenue of the Americas, New York, NY 10010

ISSN 0010-7824/98/$19.00

Contraception
1998;58:393–394

Medina, L.M., 7
Mehrotra, P.K., 137
Melis, Gian Benedetto, 289
Mink, C.P.A., 39
Mishell, Daniel R. Jr., 1, 5S, 45S, 275
Mishra, P.K., 119
Monroy, J., 7
Montanari, Tatiana, 309
Morales del Olmo, A., 7
Motta, Tiziano, 69
Mulders, T.M.T., 39

Nayak, Nihar Ranjan, 111
Nelson, Anita L., 59S
Newton, John, 215
Ngai, C.S.W., 207
Norström, Anders, 157
Noszál, Béla, 305

Oddens, B.J., 13
Ory, Howard W., 9S
Osis, Maria José D., 251

Parazzini, Fabio, 69
Patai, Kálmán, 305
Pathak, N., 119
Perez, M., 7
Perez-Palacios, G., 7
Pinto-Neto, Aarão Mendes, 351
Population Council, 257

Qian, Shao-Zhen, 315

Redmond, Geoffrey P., 29S
Reel, Jerry R., 129
Reinprayoon, Damrong, 149, 201
Rosenberg, Michael, 345
Rosenfield, Allan, 323

Salhab, Abdulazim S., 193
Sangi-Haghpeykar, Haleh, 375
Sarma, Seshu P., 387
Schnabel, Peter, 283
Schramm, W., 321
Schulz, Kenneth F., 375
Sengupta, Jayasree, 111
Shomaf, S., 193
Shulman, Lee P., 35S
Silverstein, Mark, 387
Singh, Gulshanjit, 165
Singh, M.M., 61
Sipos, Miklós, 305
Sivin, Irving, 275
Spannagi, M., 321
Srivastav, Anil, 227
Srivastava, Anil, 165
Srivastava, S., 137
Stanback, John, 357
Steiner, Markus J., 375
Stern, Janet, 275
Sulak, Patricia J., 55S
Sun, Hai-Yang, 315

Taneepanichskul, Surasak, 149
Tang, L.C.H., 207
Tang-Usaha, J., 221
Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, 261
Tejada, Ana-Sofia, 211
Telles, Eugênio, 105
Testa, Giovanna, 69
Theppitaksak, B., 221
Thonneau, Patrick, 29
Toivonen, Juhani, 361
Trussell, James, 147, 375, 379

Urbancsek, J., 109S
Urbina-Fuentes, M., 7

van Beek, Agaath A.M., 93, 283, 215
Vegetti, Walter, 69
Velazquez, E., 7
Volpe, Annibale, 289

Walker, Alexander M., 200
Wan, Livia, 275
Wang, Wayseen, 295
Wenzl, René, 283
Whaley, Kevin J., 51
Wiegratz, I., 83
Williams, Robert F., 45
Wong, A.Y.K., 207
Wong, K.S., 207

Xie, Xiao-Ying, 315

Yang, Ren-Zhu, 315

Zaneveld, Lourens J.D., 233, 239, 245, 251
Zhao, Min-Hui, 315

ELSEVIER

Contraception
1998;58:395–398

Subject Index
Volume 58
July–December 1998

Abortifacient effects, castor bean extract (rabbit), 193
Abortion
  medical methods, 257
  mifepristone + gemeprost, 99
  tamoxifen + misoprostol, 1
  vaginal gemeprost, 207
  vaginal misoprostol, 207
Achillea millefolium L. (yarrow) flowers and spermatogenesis (mouse), 309
Acne treatment, effectiveness of OC, 29S
Activated protein C (APC) ratio, association to risk of venous thromboembolism, 321
Analysis, IUD failure data, 361
Androgenicity classification, oral contraceptives, 23S
Antifertility activity
  antiprogestin CDB-2914 (rat), 129
  mifepristone (rat), 129
  phaseolinone (male rat), 183
Antiprogestogen, Org 31710, 39
Apolipoprotein levels
  effect of etonogestrel, 215
  effect of levonorgestrel, 215

Barrier contraceptive evaluation, effect of emergency contraceptive pill use, 379
Barrier methods, measuring contraceptive efficacy, 12-4
Bleeding patterns
  after medical abortion, 99
  use of Implanon®, 99S
  use of Perlutal®, 21
Bleeding/pain, predicting IUD removals, 357
Blood pressure, effect of ethinyl estradiol + desogestrel, 289
Bone density, effect of DMPA use, 351
Bowel perforations, intrauterine devices, 295

Calcified deposit formation, intrauterine devices, 305
Cardiovascular safety, oral contraceptives, 9S
Castor bean extract, abortifacient effects (rabbit), 193
Catecholamine levels, effect of ethinyl estradiol + desogestrel, 289
CDB-2914, antiprogestin, 129
CDRI 84/35, effect on spermatogenesis (rat), 175
Centchroman, effect on uterus (rat), 61, 137
Cervix
  effect of mifepristone, 157
  effect of misoprostol, 157
Characteristics preferred, vaginal contraceptives, 239
Chlamydia infection and IUD, 105
Chlorpromazin, effect on implantation (rat), 315
Clinical study
  female condom, 147
  levonorgestrel rod implants, 275
  Multiload™ 250 IUD, 201
  Norplant®-2 implants, 221
  TCu 380A, 201
  Vas deferens injectable contraceptive, 165
Colorectal tumors and OC, 335
Completing risks approach, analysis of IUD failures, 361
Condom
  female, 147
  male
    analysis of talc, 153
    contraceptive efficacy, 375
Contraceptive method use, prevalence and determinants, 29
Contraceptive testing of vaginal agents (rabbit), 51
Copper IUD
  calcified deposit formation, 305
  effect on hemoglobin and ferritin levels, 261
Cyclofem®, medroxyprogesterone acetate + estradiol cypionate, 7

Depot-medroxyprogesterone acetate (DMPA)
  effect on hemoglobin and ferritin levels, 261
  users
    effect on bone density, 351
    effect on weight change, 149
Determinants, contraceptive method use, 29
Developing countries, medical methods of abortion, 261
DMPA, *see* depot-medroxyprogesterone acetate

EDTA, effect on sperm, 35
Effectiveness of barrier contraceptives, effect of emergency contraceptive pill use, 379
Efficacy
  contraceptive barrier methods, 375
  intrauterine devices, 45S
  Implanon® implants, 91S
  Norplant® implants, 323
Emergency contraceptive pill use, during barrier contraceptive evaluation, 379
Endometrial prostaglandins, effect of mifepristone (monkey), 111
Endometrium, effect of mifepristone (rat, primate), 45

© 1998 Elsevier Science Inc. All rights reserved.
655 Avenue of the Americas, New York, NY 10010

ISSN 0010-7824/98/$19.00

Estradiol compounds, *see* specific compounds
Estradiol cypionate + medroxyprogesterone acetate, 7
Estradiol enanthate + dihydroxyprogesterone acetophenide, 21
Estrogen dose considerations, oral contraceptives, 15S
Estrogen, *see also* estradiol, ethinyl estradiol
Ethinyl estradiol + desogestrel, 289
Ethinyl estradiol + gestodene, 83
Ethinyl estradiol + levonorgestrel, 75
Ethinyl estradiol + norethindrone, 345
Etonogestrel (3-ketodesogestrel)
  effect on apolipoprotein levels, 215
  effect on hemostasis and liver function, 93
  nonmenstrual adverse event analysis, 109S
  pharmacodynamics, 91S
  pharmacokinetics, 283, 85S
Evaluation of barrier contraceptives, effect of emergency contraceptive pill use, 379

Failure data in IUD studies, analysis by competing risks approach, 345
Female condom, Reality®, 147
Ferritin level, effect of contraceptives, 261
Fluoroscopy, use in difficult removal of Norplant® implants, 387
Formulation, applicator and packaging, women's preferences for vaginal contraceptives, 245
Free levonorgestrel index level, following Norplant® implant insertion, 211

Gemeprost, termination of pregnancy, 207
Gonane progestins, 23S
Gramicidin-D, effect on sperm, 35

Hemoglobin level, effect of contraceptives, 261
Hemostatic system
  effect of etonogestrel, 93
  effect of levonorgestrel, 93
Hormonal parameters, effect of triphasic ethinyl estradiol + levonorgestrel, 75
Hyperprolactinemic patients, use of OC, 69

Ileal penetration, Multiload™-Cu 375, 295
Implanon® implants, 75S
  effect on apolipoprotein levels, 215
  effect on hemostasis and liver function, 93
  insertion and removal, 79S
  nonmenstrual adverse event analysis, 109S
  pharmacodynamics, 91S
  pharmacokinetics, 283, 85S
  vaginal bleeding pattern analysis, 99S
Implant contraceptive,
  etonogestrel, 93, 215, 283, 75S, 85S, 91S, 99S, 109S
  levonorgestrel, 93, 211, 215, 221, 261, 275, 305, 387
Implantation, effect of cholorpromazin (rat), 315
Injectable contraceptive
  depot-medroxyprogesterone acetate, 149, 261, 351
  estradiol cypionate + medroxyprogesterone acetate, 7
  estradiol enanthate + dihydroxyprogesterone acetophenide, 21
Injectable male contraceptive, styrene maleic anhydride, 165
Intrauterine device (IUD), *see also* specific devices
  appropriate candidates for use, 55S
  bowel perforations, 295
  calcified deposit formation 305
  Chlamydia infection and IUD use, 105
  copper-containing devices, 261, 305
  CuT 380A, 149
  effect on hemoglobin and ferritin levels, 261
  efficacy, 45S
  failure, analysis by competing risks approach, 361
  levonorgestrel-releasing, 275, 361
  mechanism of action, 45S
  Multiload™ 250, 201, 12-2
  Multiload™-Cu 375, 295
  Nova-T®, 361
  polyamide/plastic IUD, calcified deposit formation, 305
  practicing removals, 357
  practice guidelines, 55S, 59S
  removal, bleeding/pain predicting, 357
  safety, 45S
  stainless steel ring, 261
  TCu 380A, 201, 357
  use among women with medical problems, 59S
  weight change with IUD use, 149
Intravasal injectable contraceptive, styrene maleic anhydride (rat), 227
Introductory study, Cyclofem®, 7
IUD, *see* intrauterine device

3-Ketodesogestrel (etonogestrel), 93, 215, 283

Levonorgestrel
  effect on apolipoprotein levels, 215
  effect on hemostasis and liver function, 93
  free levonorgestrel index level, following Norplant® implant insertion, 211
Levonorgestrel rod implants, clinical trial, 275
Levonorgestrel-releasing IUD, statistical analysis of terminations, 361
Lipid metabolism
  effect of ethinyl estradiol + norgestimate, 83
  effect of triphasic ethinyl estradiol + gestodene, 83
Liver function
  effect of etonogestrel, 93
  effect of levonorgestrel, 93

Market experience, Norplant® implants, 323
Measuring contraceptive efficacy, 375
Mechanism of action, intrauterine devices, 45S

Medical methods of abortion,
bleeding patterns following procedure, 99
consensus statement, 257
gemeprost, 207
mifepristone + gemeprost, 99
misoprostol, 207
tamoxifen + misoprostol, 1
Medical problems
appropriate use of IUD, 59S
appropriate use of OC, 35S
Medroxyprogesterone acetate + estradiol cypionate, 7
Methodology, study of women's preferences for vaginal contraceptives, 233
Methotrexate, following medical abortion, 99
Mifepristone (RU 486)
effect on cervical dilatation, 157
effect on endometrial prostaglandins (monkey), 111
effect on endometrium (rat, primate), 45
Mifepristone + gemeprost, 99
Misoprostol
effect on cervical dilatation, 157
pregnancy termination, 1, 207
Monkey, 111, 119
Mouse, 309
Multiload™ 250 IUD
clinical study, 201
predicting IUD removals, 357
Multiload™-Cu 370, case report of ileal penetration, 295

Noninvasive reversal, intravasal contraception with styrene maleic anhydride (monkey), 119
Nonoxynol-9
contraceptive efficacy, 375
effect on sperm, 35
Nonsmoking/smoking women, use of OC, 35S
Norplant® implants
effect on apolipoprotein levels, 215
effect on hemoglobin and ferritin levels, 261
effect on hemostasis and liver function, 93
efficacy, 323
removal, 387
research and development, 323
review of experience, 323
Norplant® implant insertion
effect on free levonorgestrel index levels, 211
effect on sex hormone binding globulin levels, 211
Norplant®-2 implants, clinical study, 221
Nova T®, statistical analysis of terminations, 361

OC, *see* oral contraceptive
Oral contraceptive (OC)
acne treatment, 29S
androgenicity classification, 23S
cardiovascular safety, 9S
colorectal turmors and OC, 335
effect on hemoglobin and ferritin levels, 261
estrogen dose considerations, 15S
ethinyl estradiol + desogestrel, 289
ethinyl estradiol + norgestimate, 83
hyperprolactinemia, 69
practice guidelines, 35S
progestin component, 23S
treatment of acne, 29S
triphasic ethinyl estradiol + gestodene, 83
triphasic ethinyl estradiol + levonorgestrel, 75
triphasic ethinyl estradiol + norethindrone, 345
use
APC ratio and risk of venous thromboembolism, 321
effect on weight change, 345
following medical abortion, 99
smoking and OC use, 35S
use rate, effect on unintended pregnancy rate, 13
venous thromboembolism, 199
Org 31710
pharmocokinetics, 3
selective antiprogestogen, 39

Pain/bleeding, predicting IUD removals, 357
Patient types, use of IUD, 55S
Perlutal®, estradiol enanthate + dihydroxyprogesterone acetophenide, 21
Pharmacodynamics, etonogestrel, 91S
Pharmacokinetics, etonogestrel, 283, 85S
Phaseolinone
antifertility effect (male rat), 183
antileishmanial agent, 183
Polyamide/plastic IUD, calcified deposit formation, 305
Practice guidelines
intrauterine devices, 55S, 59S
oral contraceptives, 35S
Predicting IUD removals, 357
Preferences for vaginal antimicrobial contraceptives, 233, 239, 245, 251
Pregnancy termination
gemeprost, 207
tamoxifen + misoprostol, 1
Prevalence, contraceptive method use, 29
Progestin androgenicity activity, 23S
Progestin component, oral contraceptives, 23S

Rabbit, 51, 193
Radiology-digital subtraction fluoroscopy, removal of Norplant® implants, 345
Rat, 45, 61, 129, 137, 175, 183, 227, 315
Reality®, female condom, 147
Removal, Norplant® implants, 387
Removal, Implanon® implants, 79S
Research and development, Norplant® implants, 323
Reversal of styrene maleic anhydride intravasal contraceptive, use of sodium bicarbonate (rat), 227

Reversal procedure, vas occlusion with styrene maleic anhydride (monkey), 119
Ricin-A chain, abortifacient effects (rabbit), 193
Rod implants releasing levonorgestrel, clinical trial, 275
RU 486, *see* mifepristone

Safety
  antiprogestogen Org 31710 (male), 39
  intrauterine devices, 45S
  Norplant® implants, 323
Sex hormone binding globulin level, following Norplant® implant insertion, 211
Sexually transmitted diseases/AIDS protective activity, women's preferences for vaginal contraceptives, 251
Smoking and OC use, 35S
Sodium bicarbonate, reversibility of styrene maleic anhydride (rat), 227
Sperm, effects of gramicidin-D, EDTA and nonoxynol-9, 35
Spermatogenesis
  Achillea millefolium L. (yarrow) flowers (mouse), 309
  CDRI 84/35 (rat), 175
Stainless steel ring IUD, effect on hemoglobin and ferritin levels, 261
STD, *see* sexually transmitted diseases
Styrene maleic anhydride (SMA)
  clinical trial of vas deferens injectable contraceptive, 165
  intravasal contraception (monkey), 119
  intravasal injectable contraceptive (rat), 227
  reversal of SMA contraceptive (rat, monkey), 119, 227

Talc, analysis on latex condoms, 153
Tamoxifen + misoprostol, 1
TCu 380A,
  clinical study, 201
  predicting IUD removals, 12-2
Tolerability, antiprogestogen Org 31710 (male), 39

Unintended pregnancy rate, effect of OC use rate, 13
Uterus, effect of centchroman (rat), 61, 137

Vaginal agents, contraceptive testing (rabbit), 51
Vaginal antimicrobial contraceptives,
  methodology to study women's preferences, 233
  preferred characteristics, 239
  women's preferences of formulation, 245, 251
Vaginal bleeding pattern analysis, 99S
Vaginal contraceptive film (VCF®), contraceptive efficacy, 375
Vas deferens injectable contraceptive, styrene maleic anhydride, 165
Vas occlusion, styrene maleic anhydride (monkey), 119
Vascular reactivity, effect of ethinyl estradiol + desogestrel, 289
Venous thromboembolism
  association to APC ratio, 321
  OC use and venous thromboembolism, 199

Weight change
  DMPA users, 149
  IUD users, 149
  OC use, 345

Yarrow flower extract, effect on spermatogenesis (mouse), 309